Mem Inst Oswaldo Cruz, Rio de Janeiro, VOLUME 114 | JUNE 2019
Short communication

Preliminary assessment of anti-α-Gal IgG and IgM levels in patients with patent Plasmodium vivax infection

Zélia Barbosa de Almeida Coelho1, Luiza Carvalho Mourão1, Beatriz Carolina Medeiros Rodrigues1, Gustavo Pereira Cardoso-Oliveira1, Robert Hincapie2, Carlos Sanhueza-Chavez2, MG Finn2, Cor Jesus Fernandes Fontes3, Alexandre Ferreira Marques1, Érika Martins Braga1,+

1Universidade Federal de Minas Gerais, Departamento de Parasitologia, Belo Horizonte, MG, Brasil
2Georgia Institute of Technology, School of Chemistry and Biochemistry, Atlanta, GA, USA
3Universidade Federal do Mato Grosso, Faculdade de Ciências Médicas, Cuiabá, MT, Brasil

DOI: 10.1590/0074-02760190145
211 views 107 downloads
ABSTRACT

Anti-α-Gal responses may exert a protective effect in falciparum malaria. However, the biological role of such antibodies is still unknown during Plasmodium vivax infections. We investigated IgG and IgM responses to α-Gal in individuals with vivax malaria. Anti-α-Gal IgG and IgM levels were higher in these patients than in controls, but no significant correlation was found between parasitaemia and anti-α-Gal response, nor between this response and ABO blood group status. This is the first study to investigate anti-α-Gal antibodies in P. vivax-infected patients; a larger survey is necessary to achieve a better understanding of host immune response during vivax malaria.

Anti-α-Gal antibodies are natural immunoglobulins present in high concentrations in human serum that recognise glycoconjugates (Gal α1,3Gal) on cell surface expressed on all mammalian cells, except old world monkeys, apes and humans. Since this glycan is not found in humans due to the inactivation of the enzyme α-1,3-galactosyltransferase (α-1,3GT),(1) it is accepted that anti-α-Gal antibodies are generally produced in response to α-galactosyl epitopes expressed by bacteria of natural microbiotic fauna.(2, 3) Such antibodies may also be produced in response to infectious agents expressing α-Gal such as Trypanosoma sppand Leishmania spp.(4)

Because anti-α-Gal antibodies have been implicated in the removal of senescent erythrocytes, as well as in different pathological phenomena including autoimmune and parasitic diseases,(3, 5) such immunoglobulins may be exploited for different beneficial clinical applications. Recently, Yilmaz et al.(6) demonstrated that anti-α-Gal IgM antibodies are cytotoxic to Plasmodium sporozoites, inhibiting hepatocyte invasion. They also showed that immunisation against α-Gal confers protection against malaria in mice knockout for the gene α-1,3GT, suggesting that a similar approach could reduce malaria transmission in humans. Moreover a protective role for anti-α-Gal antibodies has been suggested by studies conducted with individuals from Mali(6) and children from Senegal.(7) In addition, elevated titres of anti-α-Gal antibodies have been detected in patients with acute Plasmodium falciparum infection.(8) Depending on the age of the child and the intensity of parasite exposure, the anti-αGal responses may vary. It has been demonstrated that anti-αGal IgM is protective, followed by IgG3 and IgG4 anti-αGal antibodies.(9) However, most of these studies have been conducted with patients with falciparum malaria; whether anti-α-gal antibodies confer protection to Plasmodium vivax infection remains unknown. Here, we assessed IgG and IgM antibody response to α-Gal in patients with patent P. vivax infection from Cuiabá, state of Mato Grosso, Brazil (n = 112) (Table), and as controls, malaria-naïve individuals who lived in a non-endemic area and who had never been exposed to malaria (Belo Horizonte, state of Minas Gerais, Brazil) (n = 20). This study was conducted according to the principles expressed in the Declaration of Helsinki and approved by the Ethics Committee of the National Information System on Research Ethics Involving Human Beings (Sisnep – CAAE01496013.8.0000.5149). All healthy donors and patients were anonymised, and they provided written informed consent for the collection of samples and subsequent analysis.

 

 

IgG and IgM anti-α-Gal were detected in plasma samples by enzyme-linked immunosorbent assay (ELISA) using 30 nm diameter bacteriophage Qβ virus like particles (Qβ-VLPs), displaying approximately 540 α-Gal molecules.(10) Briefly, each well of a 96-well, flat-bottomed, polystyrene microplate (Corning Incorporation, Corning, NY, USA) was coated with 10 ng of Qβ-(αGal)540 particle in bicarbonate-carbonate buffer (pH 9.6; 0.1 M) and incubated overnight at 4ºC. Plates were blocked with 1% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) pH 7.4 and kept at 37ºC for 1 hour; then, plasma samples diluted 1:100 in PBS/BSA were added and wells were incubated for 90 minutes at 37ºC. After three washes with PBS containing 0.05% (v/v) PBS Tween 20 (PBST), plates were incubated with biotinylated anti-human IgG or IgM, diluted, respectively, 1:4,000 and 1:5,000 in PBST for 30 minutes at 37ºC. Next, plates were rewashed and streptavidin-horseradish peroxidase (HRP) conjugate diluted 1:4,000 in PBST was added and maintained at 37ºC for 30 minutes. Binding was revealed using 0.5 mg/mL o-phenylenediamine dihydrochloride (OPD) substrate (Sigma-Aldrich, St Louis, MO, USA) in 0.05 M phosphate-citrate buffer, pH 5.0 and the reaction was stopped with 3 M H2SO4. Optical density (OD)492 nm was determined in a Spectra Max 250 microplate reader (Molecular Devices, Sunnyvale, CA, USA). Control measurements with underivatised Qβ particles showed no background binding by serum antibodies (data not shown).

P. vivax infection may increase anti-α-Gal IgG and IgM levels (Figure), data which are in accordance with previous findings for P. falciparum-infected patients.(8) However, the magnitude of the anti-α-Gal responses were lower in patients with vivax malaria. Since anti-α-Gal antibodies are involved in different processes that contribute to allergies, such as tick-induced red meat allergy,(11, 12) autoimmune and “autoimmune-like” pathogeneses,(5, 13) it is therefore possible that such antibodies may also play an important role in P. vivax infection. Although it has been demonstrated that IgG and IgM antibody responses to α-Gal vary according to age in P. falciparum infection,(9) we found no significant age dependence in this study (Spearman’s correlation r = 0.2023, p = 0.0603 to IgG and r = -0.1339, p = 0.2163 to IgM).

 

 

We also evaluated the influence of parasitaemia, determined by examination of 200 fields at 1000x magnification under oil-immersion, on IgG and IgM responses to α-Gal. No significant correlation of parasitaemia with the levels of anti-α-Gal IgG or IgM was detected (Spearman’s correlation r = 0.2363, p = 0.0285 and r = 0.0291, p = 0.7899, respectively), but the scatter in the data is sufficiently large to suggest that a larger analysis is warranted.

Taking into account the fact that the blood antigen B [Galα1-3(Fucα1,2)Gal] and the α-Gal glycan share a terminal Galα1-3 motif, and considering that individuals with blood type B have reduced antibody responses to α-Gal(14, 15) and are more susceptible to pathogens that express such antigen in their surface,(6, 7) the effect of ABO blood type on immune responses to α-Gal in P. vivax-infected patients was also investigated. The ABO blood group was determined by reverse typing, testing each plasma (99 patients and 18 controls) (Supplementary Table) for the presence of anti-A and anti-B antibodies using known A and B erythrocytes (Revercel ® , Fresenius Kabi, São Paulo, SP, Brazil). We did not found an association between anti-α-Gal IgG or IgM levels and blood type in subjects with patent P. vivax infection (Kruskal-Wallis followed by Dunn’s multiple comparison test p = 0.1740 and p = 0.2811, respectively).

Because IgG autoantibodies are involved in phagocytosis and complement-mediated cell lysis, establishing how well such immunoglobulins interact with the clearance system may provide valuable information to understand the host immune response during vivax malaria. To determine whether IgG anti-α-Gal was able to enhance innate clearance of non-infected erythrocytes from different blood groups, an assay was conducted as previously reported.(16) Although we might expect B-type red blood cells to be less recognised by anti-α-Gal antibodies because of the molecular similarity of these two antigens, we observed no significant difference in erythrophagocytosis using erythrocytes from A, B or O blood groups. Such results suggest that opsonisation of non-infected erythrocytes by anti-α-Gal IgG is independent of ABO antigens, although it has already been demonstrated that differences in blood group antigen expression may affect susceptibility to other infections.(17)

Since early 1990s, glycoproteins and natural glycolipids have been shown to be important components of the adaptive immunological repertoire. Currently, there are no vaccines in use against more complex parasites such as Plasmodium spp, which leads to the necessity to identify antigens that are targets of naturally acquired antibodies against such important parasite. Further studies of anti-α-Gal response in different endemic populations are necessary to better elucidate the functional activity of anti-α-Gal antibodies in this context.

 

ACKNOWLEDGEMENTS

 

To all patients and their families who contributed to the current study, to health professionals and students from Federal University of Mato Grosso and to Dr Igor Correia de Almeida and Dr Ricardo Tostes Gazzinelli, who have kindly endowed the antibodies utilised in this study.

 

AUTHORS' CONTRIBUTION

 

Conceived and designed the experiments: ZBAC, LCM, AFM, EMB. Performed the experiments: ZBAC, BCMR, GPC-O. Analysed the data: ZBAC, LCM, EMB. Contributed reagents/materials/analysis tools: MGF, CS-C, RH, CJFF, AFM, EMB. Wrote the manuscript: LCM, GPC-O, AFM, EMB. The authors state that all data presented in this manuscript is original and has not been published elsewhere.

REFERENCES
01. Galili U, Swanson K. Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci U S A. 1991; 88(16): 7401-4.
02. Macher BA, Galili U. The Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta. 2008; 1780(2): 75-88.
03. Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffis JM. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun. 1988; 56(7): 1730-7.
04. Avila JL, Rojas M, Galili U. Immunogenic Gal alpha 1----3Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. J Immunol. 1989; 142(8): 2828-34.
05. Galili U, Flechner I, Rachmilewitz A. A naturally occurring anti-alpha-galactosyl IgG recognizing senescent human red cells. Prog Clin Biol Res. 1985; 195: 263-78.
06. Yilmaz B, Portugal S, Tran TM, Gozzelino R, Ramos S, Gomes J, et al. Gut microbiota elicits a protective immune response against malaria transmission. Cell. 2014; 159(6): 1277-89.
07. Cabezas-Cruz A, Mateos-Hernández L, Alberdi P, Villar M, Riveau G, Hermann E, et al. Effect of blood type on anti-α-Gal immunity and the incidence of infectious diseases. Exp Mol Med. 2017; 49(3): e301.
08. Ravindran BA, Satapathy K, Das MK. Naturally-occurring anti-alpha-galactosyl antibodies in human Plasmodium falciparum infections – A possible role for autoantibodies in malaria. Immunol Lett. 1988; 19(2): 137-41.
09. Aguilar R, Ubillos I, Vidal M, Balanza N, Crespo N, Jiménez A, et al. Antibody responses to α-Gal in African children vary with age and site and are associated with malaria protection. Sci Rep. 2018; 8(1): 9999.
10. Brito CRN, McKay CS, Azevedo MA, Santos LCB, Venuto AP, Nunes DF, et al. Virus-like particle display of the α-Gal epitope for the diagnostic assessment of Chagas disease. ACS Infect Dis. 2016; 2(12): 917-22.
11. Commins SP, Satinover SM, Hosen J, Mozena J, Borish L, Lewiss BD, et al. Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-α-1,3-galactose. J Allergy Clin Immunol. 2008; 123(2): 426-33.
12. Araujo RN, Franco PF, Rodrigues H, Santos LCB, McKay CS, Sanhueza CA, et al. Amblyomma sculptum tick saliva: α-Gal identification, antibody response and possible association with red meat allergy in Brazil. Int J Parasitol. 2016; 46: 213-20.
13. Galili U. Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody. Springer Semin Immunopathol. 1993; 15(2-3): 155-71.
14. Rispens T, Derksen NIL, Commins SP, Platss-Mills TA, Aalberse RC. IgE production to α-Gal is accompanied by elevated levels of specific IgG1 antibodies and low amounts of IgE to blood group B. PloS One. 2013; 8(2): e55566.
15. Muthana SM, Gildersleeve JC. Factors affecting anti-glycan IgG and IgM repertoires in human serum. Sci Rep. 2016; 6(January): 19509.
16. Mourão LC, Roma PMS, Aboobacar JSS, Medeiros CMP, Almeida ZB, Fontes CJF, et al. Anti-erythrocyte antibodies may contribute to anaemia in Plasmodium vivax malaria by decreasing red blood cell deformability and increasing erythrophagocytosis. Malar J. 2016; 15(1): 397.
17. Cooling L. Blood groups in infection and host susceptibility. Clin Microbiol Rev. 2015; 28 (3): 801-70.

Financial support: CNPq (grants 309202/2013-2; 158045/2015-7; 404365/2016-7), Fundep (grant APQ000361-16), Capes (PNPD PG/PARASITOLOGIA), Children’s Healthcare of Atlanta. ZBAC and LCM contributed equally to this work.The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
+ Corresponding author: embraga@icb.ufmg.br
 https://orcid.org/0000-0001-5550-7157
Received 25 April 2019
Accepted 17 June 2019

Citation: Coelho ZBA, Mourão LC, Rodrigues BCM, Cardoso-Oliveira GP, Hincapie R, Sanhueza-Chavez C, et al. Preliminary assessment of anti-?-Gal IgG and IgM levels in patients with patent Plasmodium vivax infection. Mem Inst Oswaldo Cruz. 2019; 114: e190145.

Our Location

Memórias do Instituto Oswaldo Cruz

Av. Brasil 4365, Castelo Mourisco 
sala 201, Manguinhos, 21040-900 
Rio de Janeiro, RJ, Brazil

Tel.: +55-21-2562-1222

This email address is being protected from spambots. You need JavaScript enabled to view it.

Support Program

logo fiocruz logo governo
logo faperj logo cnpq marca capes